# A Phase I Study of LX-039 Tablets

> **NCT04097756** · PHASE1 · COMPLETED · sponsor: **Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.** · enrollment: 44 (actual)

## Conditions studied

- Advanced Breast Cancer

## Interventions

- **DRUG:** LX-039 tablets

## Key facts

- **NCT ID:** NCT04097756
- **Lead sponsor:** Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-07
- **Primary completion:** 2022-08-08
- **Final completion:** 2023-02-07
- **Target enrollment:** 44 (ACTUAL)
- **Last updated:** 2023-05-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04097756

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04097756, "A Phase I Study of LX-039 Tablets". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04097756. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*